The origin and role of human CD21low B cells in autoimmune disease

The origin and role of human CD21low B cells in autoimmune disease - AAV21low

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004710

Enrollment

Registered

2014-02-24

Start date

2013-07-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M05.8 M32.9 M35 M31

Interventions

Group 1: Examination of the origin and role of CD21low B cells in patients with ANCA associated AAV. Peripheral blood was taken and B cells analyzed for CD21low B cells. These were characterized for p

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: arm 1: patients with solid diagnosis of ANCA associated vasculitis and detectable B cells arm 2: patients with collagenosis and detectable B cells arm 3: healthy subjects all: signed informed consent

Exclusion criteria

Exclusion criteria: - current steroid dose > 15mg/day prednison equivalent - lack of signed informed consent - pregnant women

Design outcomes

Primary

Measure	Time frame
Identification of underlying common origin of CD21low B cells	—

Secondary

Measure	Time frame
a) Characterization of altered signalling in switched and non-switched CD21low B cells and its regulation by inhibitory receptors b) Identification of the functional role of CD21low B cells in inflammation	—

Countries

Germany

Contacts

Public ContactKlaus Warnatz

Universitätsklinikum Freiburg Centrum für Chronische Immundefizienz, CCI

klaus.warnatz@uniklinik-freiburg.de0761 270 77640

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026